Iron chelation therapy in thalassemia major: A systematic review with meta-analyses of 1520 patients included on randomized clinical trials

Aurelio Maggio, Aldo Filosa, Angela Vitrano, Giuseppina Aloj, Antonis Kattamis, Adriana Ceci, Suthat Fucharoen, Paolo Cianciulli, Robert W. Grady, Luciano Prossomariti, John B. Porter, Angela Iacono, Maria Domenica Cappellini, Fedele Bonifazi, Filippo Cassarà, Paul Harmatz, John Wood, Christian Gluud

Research output: Contribution to journalArticle

Abstract

The effectiveness of deferoxamine (DFO), deferiprone (DFP), or deferasirox (DFX) in thalassemia major was assessed. Outcomes were reported as means±SD, mean differences with 95% CI, or standardized mean differences. Statistical heterogeneity was tested using Χ 2 (Q) and I 2. Sources of bias and Grading of Recommendations Assessment, Development and Evaluation system (GRADE) were considered. Overall, 1520 patients were included. Only 7.4% of trials were free of bias. Overall measurements suggest low trial quality (GRADE). The meta-analysis suggests lower final liver iron concentrations during associated versus monotherapy treatment (p

Original languageEnglish
Pages (from-to)166-175
Number of pages10
JournalBlood cells, molecules & diseases
Volume47
Issue number3
DOIs
Publication statusPublished - Oct 15 2011

Fingerprint

Chelation Therapy
beta-Thalassemia
Meta-Analysis
Iron
Randomized Controlled Trials
Deferoxamine
Liver
Therapeutics
deferiprone
deferasirox

ASJC Scopus subject areas

  • Molecular Biology
  • Molecular Medicine
  • Hematology
  • Cell Biology

Cite this

Iron chelation therapy in thalassemia major : A systematic review with meta-analyses of 1520 patients included on randomized clinical trials. / Maggio, Aurelio; Filosa, Aldo; Vitrano, Angela; Aloj, Giuseppina; Kattamis, Antonis; Ceci, Adriana; Fucharoen, Suthat; Cianciulli, Paolo; Grady, Robert W.; Prossomariti, Luciano; Porter, John B.; Iacono, Angela; Cappellini, Maria Domenica; Bonifazi, Fedele; Cassarà, Filippo; Harmatz, Paul; Wood, John; Gluud, Christian.

In: Blood cells, molecules & diseases, Vol. 47, No. 3, 15.10.2011, p. 166-175.

Research output: Contribution to journalArticle

Maggio, A, Filosa, A, Vitrano, A, Aloj, G, Kattamis, A, Ceci, A, Fucharoen, S, Cianciulli, P, Grady, RW, Prossomariti, L, Porter, JB, Iacono, A, Cappellini, MD, Bonifazi, F, Cassarà, F, Harmatz, P, Wood, J & Gluud, C 2011, 'Iron chelation therapy in thalassemia major: A systematic review with meta-analyses of 1520 patients included on randomized clinical trials', Blood cells, molecules & diseases, vol. 47, no. 3, pp. 166-175. https://doi.org/10.1016/j.bcmd.2011.07.002
Maggio, Aurelio ; Filosa, Aldo ; Vitrano, Angela ; Aloj, Giuseppina ; Kattamis, Antonis ; Ceci, Adriana ; Fucharoen, Suthat ; Cianciulli, Paolo ; Grady, Robert W. ; Prossomariti, Luciano ; Porter, John B. ; Iacono, Angela ; Cappellini, Maria Domenica ; Bonifazi, Fedele ; Cassarà, Filippo ; Harmatz, Paul ; Wood, John ; Gluud, Christian. / Iron chelation therapy in thalassemia major : A systematic review with meta-analyses of 1520 patients included on randomized clinical trials. In: Blood cells, molecules & diseases. 2011 ; Vol. 47, No. 3. pp. 166-175.
@article{7a69806acfe344c6b82cfdf8497327a9,
title = "Iron chelation therapy in thalassemia major: A systematic review with meta-analyses of 1520 patients included on randomized clinical trials",
abstract = "The effectiveness of deferoxamine (DFO), deferiprone (DFP), or deferasirox (DFX) in thalassemia major was assessed. Outcomes were reported as means±SD, mean differences with 95{\%} CI, or standardized mean differences. Statistical heterogeneity was tested using Χ 2 (Q) and I 2. Sources of bias and Grading of Recommendations Assessment, Development and Evaluation system (GRADE) were considered. Overall, 1520 patients were included. Only 7.4{\%} of trials were free of bias. Overall measurements suggest low trial quality (GRADE). The meta-analysis suggests lower final liver iron concentrations during associated versus monotherapy treatment (p",
author = "Aurelio Maggio and Aldo Filosa and Angela Vitrano and Giuseppina Aloj and Antonis Kattamis and Adriana Ceci and Suthat Fucharoen and Paolo Cianciulli and Grady, {Robert W.} and Luciano Prossomariti and Porter, {John B.} and Angela Iacono and Cappellini, {Maria Domenica} and Fedele Bonifazi and Filippo Cassar{\`a} and Paul Harmatz and John Wood and Christian Gluud",
year = "2011",
month = "10",
day = "15",
doi = "10.1016/j.bcmd.2011.07.002",
language = "English",
volume = "47",
pages = "166--175",
journal = "Blood Cells, Molecules, and Diseases",
issn = "1079-9796",
publisher = "Academic Press Inc.",
number = "3",

}

TY - JOUR

T1 - Iron chelation therapy in thalassemia major

T2 - A systematic review with meta-analyses of 1520 patients included on randomized clinical trials

AU - Maggio, Aurelio

AU - Filosa, Aldo

AU - Vitrano, Angela

AU - Aloj, Giuseppina

AU - Kattamis, Antonis

AU - Ceci, Adriana

AU - Fucharoen, Suthat

AU - Cianciulli, Paolo

AU - Grady, Robert W.

AU - Prossomariti, Luciano

AU - Porter, John B.

AU - Iacono, Angela

AU - Cappellini, Maria Domenica

AU - Bonifazi, Fedele

AU - Cassarà, Filippo

AU - Harmatz, Paul

AU - Wood, John

AU - Gluud, Christian

PY - 2011/10/15

Y1 - 2011/10/15

N2 - The effectiveness of deferoxamine (DFO), deferiprone (DFP), or deferasirox (DFX) in thalassemia major was assessed. Outcomes were reported as means±SD, mean differences with 95% CI, or standardized mean differences. Statistical heterogeneity was tested using Χ 2 (Q) and I 2. Sources of bias and Grading of Recommendations Assessment, Development and Evaluation system (GRADE) were considered. Overall, 1520 patients were included. Only 7.4% of trials were free of bias. Overall measurements suggest low trial quality (GRADE). The meta-analysis suggests lower final liver iron concentrations during associated versus monotherapy treatment (p

AB - The effectiveness of deferoxamine (DFO), deferiprone (DFP), or deferasirox (DFX) in thalassemia major was assessed. Outcomes were reported as means±SD, mean differences with 95% CI, or standardized mean differences. Statistical heterogeneity was tested using Χ 2 (Q) and I 2. Sources of bias and Grading of Recommendations Assessment, Development and Evaluation system (GRADE) were considered. Overall, 1520 patients were included. Only 7.4% of trials were free of bias. Overall measurements suggest low trial quality (GRADE). The meta-analysis suggests lower final liver iron concentrations during associated versus monotherapy treatment (p

UR - http://www.scopus.com/inward/record.url?scp=80053385222&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80053385222&partnerID=8YFLogxK

U2 - 10.1016/j.bcmd.2011.07.002

DO - 10.1016/j.bcmd.2011.07.002

M3 - Article

C2 - 21843958

AN - SCOPUS:80053385222

VL - 47

SP - 166

EP - 175

JO - Blood Cells, Molecules, and Diseases

JF - Blood Cells, Molecules, and Diseases

SN - 1079-9796

IS - 3

ER -